We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Another Chinese drugmaker has run afoul of the FDA. After banning the imports of Hangzhou Guoguang Touring Commodity in October, the agency has now slapped its finished pharmaceutical plant with a warning letter.